公开(公告)号：KR1020140102811A

公开(公告)日：2014-08-25

申请号：KR1020130016130

申请日：2013-02-15

Applicant: 강원대학교산학협력단

Inventor： 정유진 ,  최원석 ,  우윤서 ,  조정현

IPC: A61K31/437 ,  A61P35/00

CPC classification number: A61K31/4745 ,  A61K9/14 ,  A61K9/16 ,  A61K9/20 ,  A61K9/48 ,  A61K31/437

Abstract: The present invention relates to a use of imiquimod as an adjuvant for cancer treatment. The inventors have revealed that imiquimod, which is a stimulator of TLR7, promotes apoptosis by causing self-predation by the generation of free radicals in a result of treating the imiquimod to liver cancer, melanoma cancer, and chemotherapy resistant melanoma cancer that have resistance to anticancer agents for colon cancer and EGFR over-expressed colon cancer. Therefore, the imiquimod can be used as an adjuvant for cancer treatment for chemotherapy resistant cancer.

Abstract translation: 本发明涉及咪喹莫特作为癌症治疗佐剂的用途。 本发明人已经揭示了作为TLR7刺激剂的咪喹莫特通过在将咪喹莫特治疗到具有耐药性的肝癌，黑素瘤癌症和抗化学药物的黑素瘤癌症的结果中引起自由基的产生而促进凋亡 抗癌剂用于结肠癌和EGFR过表达结肠癌。 因此，咪喹莫特可以用作化疗耐药性癌症的癌症治疗佐剂。